Optiscan has been featured in Stockhead in an article examining Australia’s growing focus on sovereign manufacturing and the role local healthcare companies are playing in developing and exporting advanced medical technologies.

The article highlights Optiscan’s vertically integrated approach, with its confocal endomicroscopy systems developed and manufactured at the company’s global headquarters in Mulgrave, Melbourne. It also references the recent US launch of InSpecta and the company’s October FDA 510(k) submissions for its InForm digital pathology and InVue precision surgery platforms, positioning Optiscan as an example of Australian-developed medical technology being manufactured locally for international markets.

CEO and Managing Director Dr. Camile Farah said: “Australia has a strong track record of medical innovation, but the real opportunity is ensuring we have the manufacturing capability to translate that innovation into globally competitive products.”

He added: “It’s not just about what we can develop in Australia, but what we can build, commercialise and export to the world.”

Stockhead – Read the full article here.